

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy

Masatoshi Kudo

Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Keywords

Hepatocellular carcinoma · Systemic therapy · Locoregional therapy · Clinical complete response · Drug-off criteria

Introduction

Hepatocellular carcinoma (HCC) is refractory to treatment under the following conditions: (A) a large number of tumors, (B) large tumor size, (C) vascular invasion or extrahepatic spread, and (D) poorly differentiated HCC [1]. Curative treatment options include liver transplantation, resection, and ablation, such as radiofrequency ablation (RFA) or microwave ablation, which yield the best outcomes in patients with HCC confined to the liver [1, 2]. However, HCCs with a high tumor burden or microscopic vascular invasion, and confluent multinodular gross type or poorly differentiated pathological type HCCs, have a high recurrence rate after curative therapy, and achieving a complete cure is difficult in these cases [1–5].

Because of its high response rate and good tolerability, the combination of atezolizumab plus bevacizumab is the first-line systemic therapy regimen for HCC [6–10]. In cases in which bevacizumab is not indicated, durvalumab plus tremelimumab is the recommended treatment regimen (Fig. 1) [11–15]. In patients who are not eligible for or intolerant to combination immunotherapy, molecular



Prof. M. Kudo

A handwritten signature in black ink, appearing to read 'Masatoshi Kudo'.

Editor Liver Cancer

targeted agents such as lenvatinib [16] are the first-line option (Fig. 1). In patients with intermediate-stage HCC not suitable for transarterial chemoembolization (TACE) [17, 18], atezolizumab plus bevacizumab combination immunotherapy combined with locoregional therapy such as TACE, ablation, or resection can achieve high complete response (CR) rates, as well as a durable deep response (Fig. 2) [19–22]. One important issue that needs to be resolved is establishing the optimal criteria to discontinue systemic therapy after CR is achieved with systemic therapy alone or drugs plus locoregional therapy. However, there were no clear criteria prior to a recent report [22]. This Editorial introduces the recently proposed criteria of “Clinical CR” and the “Drug-off Criteria” after imaging CR is achieved and discusses their validity.




Fig. 1. First-line treatment strategy for advanced-stage hepatocellular carcinoma. EIS, endoscopic injection sclerotherapy; EVL, endoscopic variceal ligation; UPCR, urine protein creatinine ratio; CP-A, Child-Pugh grade A; CP-B, Child-Pugh grade B; IO, immuno-oncology.




Fig. 2. Effect of adding locoregional therapy to systemic therapy in intermediate-stage hepatocellular carcinoma (HCC). Systemic therapy alone cannot achieve pathological complete response (CR) even in intermediate-stage HCC. During the best response is maintained, addition of locoregional therapy (resection, ablation, super-selective TACE) can achieve high rate of pathological CR. Even though CR is not achieved deep and durable response is achieved from stable disease (SD) and partial response (PR).

Table 1. Definition of clinical CR and drug-off criteria in immunotherapy combined with locoregional therapy

Definition of clinical CR
Fulfilling the following 2 conditions 1. Achievement of CR per mRECIST/RECISTv1.1 evaluated by CT/MRI 2. Continuous normalization of 3 tumor markers (AFP/AFP-L3/PIVKA-II) more than 6 weeks
Drug-off criteria
Fulfilling the following 3 conditions 1. Achievement of CR per mRECIST (RECISTv1.1) by super-selective TACE/RFA/MWA 2. Continuous normalization of 3 tumor markers (AFP/AFP-L3/PIVKA-II) more than 12–24 weeks 3. Complete disappearance of intranodular arterial flow by CEUS
CR, complete response; AFP, alpha-fetoprotein; AFP-L3, alpha-fetoprotein isoform, lectin affinity; PIVKA-II, protein induced by vitamin K absence or antagonist-II; CEUS, contrast-enhanced ultrasonography. Cited from Kudo et al. [22].

High Rate of CR by Combination Treatment with Systemic and Locoregional Therapy

Until recently, TACE was the only recommended treatment for intermediate-stage HCC according to the Barcelona Clinic Liver Cancer treatment algorithm [23] in addition to EASL [24] and AASLD [25] clinical practice guidelines. If liver function is preserved and there is no vascular invasion or extrahepatic spread, the Hepatocellular Carcinoma Clinical Practice Guidelines by the Japan Society of Hepatology (JSH) [26] recommends systemic therapy in addition to TACE for patients with a primary tumor >3 cm in diameter or more than four multifocal tumors. Intermediate-stage HCC comprises a heterogeneous population in terms of tumor number, tumor size, and liver function. Although TACE has been the standard of care for intermediate-stage HCC, achieving a cure with TACE alone is difficult. The concept of “TACE refractory” [27, 28] or “TACE unsuitable” [17, 18] was proposed in recent years, resulting in a gradual shift in treatment strategies that prioritize upfront systemic therapy followed by TACE over TACE alone for patients with good liver function and a high tumor burden who are not suitable for TACE [17–19, 21, 29, 30].

Intermediate-stage HCC is a locally advanced cancer; therefore, it is important to maximize treatment efficacy while maintaining liver function and managing adverse events. If a deep response is achieved using systemic therapy, locoregional therapy should be added as soon as possible while the response is maintained to achieve a CR or, deep and durable partial response (Fig. 2.) [22].

For combination therapy consisting of systemic therapy and locoregional therapy including TACE, RFA, and resection, the conventional response evaluation criteria are

not sufficient. For example, RECISTv1.1 does not account for complete pathologic necrosis of HCC with Lipiodol deposition due to conventional TACE [31]. Furthermore, mRECIST criteria require subtraction imaging to accurately assess complete pathologic necrosis [32].

A new criterion for clinical CR was recently proposed [22]. This criterion is defined as follows: (A) CR according to mRECIST/RECISTv1.1 assessed by CT/MRI, and (B) normalization of three tumor markers (AFP/AFP-L3/PIVKA-II) and maintenance of normal values for at least 6 weeks (Table 1). Although it remains to be validated compared with pathological findings, it is a simple diagnostic method that is associated with good treatment outcomes, as discussed later.

CR Rates with Single Agent Systemic Therapy

Table 2 summarizes the outcomes of systemic therapies currently approved by the FDA, EMA, and Japan for unresectable HCC [6, 7, 11, 16, 33–36]. The CR rate by RECISTv1.1 is <1% for molecular targeted agents (lenvatinib, sorafenib, ramucirumab, cabozantinib, and regorafenib). HCC is currently the most common malignant neoplasm among primary malignancies of the digestive system that regress spontaneously or go into remission (HCC accounts for 49.5%, 193/390 cases, of all digestive cancers) [37]. The number of cases of spontaneous regression exceeds the number of cases achieving CR after treatment with sorafenib. Therefore, achieving CR after monotherapy with molecular targeted agents is rare.

However, 7.7% of patients treated with atezolizumab plus bevacizumab and 3.1% of patients treated with durvalumab plus tremelimumab achieved a CR according to

Table 2. Efficacy results of systemic therapy

	IMbrave150 trial	HIMALAYA trial	RELECT trial	SHARP trial	REACH-2 trial	CELESTIAL trial	RESORSE trial
	atezolizumab plus bevacizumab (Ref. 6, 7)	durvalumab plus tremelimumab (Ref. 11)	lenvatinib (Ref. 16)	sorafenib (Ref. 33)	ramucirumab (Ref. 34)	cabozantinib (Ref. 36)	regorafenib (Ref. 35)
Median OS, months	19.2 (95% CI: 17.0–23.7)	16.4 (95% CI: 14.2–19.6)	13.6 (95% CI: 12.1–14.9)	10.7 (95% CI: 9.4–13.3)	8.5 (95% CI: 7.0–10.6)	10.2 (95% CI: 9.1–12.0)	10.6 (95% CI: 9.1–12.1)
Median PFS, months	6.9 (95% CI: 5.7–8.6)	3.8 (95% CI: 3.68–5.32)	7.4 (95% CI: 6.9–8.8)	(TTP) 5.5 (95% CI: 4.1–6.9)	2.8 (95% CI: 2.8–4.1)	5.52 (95% CI: 4.0–5.5)	3.1 (95% CI: 2.8–4.1)
CR, %	7.7 (n = 25)	3.1 (n = 12)	<1 (n = 2)	0 (n = 0)	0 (n = 0)	0 (n = 0)	1 (n = 2)
RECISTv1.1							
ORR, %	29.8 (95% CI: 24.8–35.0)	20.1 (95% CI: NA)	24.1 (95% CI: 20.2–27.9)	2 (95% CI: NA)	4.6 (95% CI: 1.7–7.5)	4.0 (95% CI: 2.8–7.7)	10 (95% CI: 7–14)
DCR, %	73.6 (95% CI: NA)	60.1 (95% CI: NA)	75.5 (95% CI: 71.7–79.4)	43 (95% CI: NA)	59.9 (95% CI: 53.1–66.7)	64 (95% CI: NA)	65 (95% CI: NA)

NA, not available; TTP, time to progression; CR, complete response; ORR, objective response rate; DCR, disease control rate; OS, overall survival; PFS, progression-free survival.

RECISTv1.1, which is a promising result in terms of CR in unresectable HCC after 2020, when combination immunotherapy became available in the routine clinical practice. However, CR by imaging alone is not an accurate indication of pathological CR without subsequent recurrence.

CR Rate with the Combination of Systemic and Locoregional Therapy

Table 3 summarizes the results of combination treatment with drugs and locoregional therapy. In intermediate-stage HCC, the TACTICS trial showed that the combination of TACE plus sorafenib yields a CR rate of 28.8% and median PFS of 25.2 months, which is significantly better than the outcomes of TACE alone [38, 39]. In the TACTICS-L trial, lenvatinib plus TACE resulted in a CR rate of 66.1% and a median PFS of 28.0 months [40].

In patients with advanced-stage HCC, a multicenter randomized controlled trial (LAUNCH study) comparing lenvatinib alone with lenvatinib plus on-demand TACE (LEN+TACE) [41] showed a favorable ORR of 54.1% and a median PFS of 10.6 months. Downstaging with LEN+TACE enabled conversion surgery in 15.3% (26/170) of patients, and complete pathologic necrosis was observed in 1.2% (2/170) of patients. Similarly, the LEOPARD trial, which tested the combination of CDDP and lenvatinib in advanced-stage HCC, reported an ORR of 64.7% and PFS of 6.3 months according to mRECIST [42]. Thus, the combination of systemic therapy and locoregional therapy in both intermediate-stage HCC and

advanced-stage HCC is gradually becoming a major trend worldwide due to its favorable outcomes [30].

A recent multicenter proof-of-concept study [22] reported the results of the combination of atezolizumab plus bevacizumab as initial therapy followed by curative conversion treatments such as resection, super-selective TACE, or ablation for TACE-unsuitable patients with early- to intermediate-stage HCC and good liver function (atezolizumab plus bevacizumab followed by curative conversion therapy: ABC conversion therapy). The study reported a clinical CR rate of 34.5% (38/110 patients) based on the definition of clinical CR provided earlier (Table 1). In patients who achieved partial response or stable disease with Atezo/Bev, CR or deep partial response can be achieved with the addition of locoregional therapy before the development of PD (Fig. 2). Although the results cannot be simply compared, the percentage of patients achieving CR in response to the combination of systemic and locoregional therapy is increasing compared with that of patients treated with systemic therapy alone or locoregional therapy alone. In addition, in patients who fulfilled the drug-off criteria (Table 1), there was no recurrence during the 21.2 months follow-up period. In that sense, this drug-off criteria highly suggest pathological CR. A multicenter, prospective, randomized phase 3 trial (IMPACT trial) was initiated in Japan in July 2023 to validate this favorable result [22] (Fig. 3).

Currently, several phase 3 trials are ongoing to confirm the favorable results of the combination of TACE and immunotherapy in prospective randomized controlled trials. In particular, the TALENTACE trial, which evaluates the combination of TACE and atezolizumab plus

Table 3. Efficacy results by combination of systemic plus locoregional therapy

	TACTICS trial	TACTICS-L trial	ABC conversion	LAUNCH trial	LEOPARD trial
	sorafenib+TACE (Ref.38, 39) (n = 80)	lenvatinib+TACE (n = 62) (Ref. 40)	atezolizumab plus bevacizumab+TACE/RFA/ resection (n = 110) (Ref. 22)	lenvatinib+TACE (n = 170) (Ref. 41)	lenvatinib+CDDP HAIC (n = 36) (Ref. 42)
	intermediate stage	intermediate stage	intermediate stage	advanced stage	advanced stage
Median OS, months	36.2 (95% CI: 30.5–44.1)	NR (90% CI: 35.5-NR)	NR	17.8 (95% CI: 16.1–19.5)	17.2 (95% CI: 10.9-NR)
Median PFS, months	22.8 (95% CI: 18.4–27.5)	28.0 (90% CI: 25.1–31.0)	NR	10.6 (95% CI: 9.5–11.7)	6.3 (95% CI: 5.1–7.9)
CR, % (mRECIST)	28.8 (n = 23)	66.1 (n = 41)	35.5 (n = 39)	2.9 (n = 5)	29.4 (n = 10)
Clinical CR*, %	NA	NA	34.5 (n = 38) (drug-free in 23%)	15.3 (n = 26)**	NA
ORR, % (mRECIST)	71.3 (95% CI: NA)	85.5 (90% CI: 76.0–92.2)	90.5 (95% CI: NA)	54.1 (95% CI: NA)	64.7 (95% CI: 46.5–80.3)
DCR, %	83.8 (95% CI: NA)	91.9 (90% CI: NA)	100.0 (95% CI: NA)	94.2 (95% CI: NA)	76.5 (95% CI: 58.8–89.3)

NA, not available; NR, not reached; AFP, alpha-fetoprotein; AFP-L3, alpha-fetoprotein isoform, lectin affinity; PIVKA-II, protein induced by vitamin K absence or antagonist-II. *mRECIST CR with normalized AFP, AFP-L3, and PIVKA-II levels >6 weeks. **Curative resection after downstaging by LEN+TACE.




Fig. 3. Current ongoing phase 3 clinical trials in hepatocellular carcinoma.

bevacizumab [43], the ABC HCC trial [44], the EMERALD-1 trial, the EMERALD-3 trial [45], and the LEAP-012 trial [46] are expected to show positive results (Fig. 3).

Can Drugs Be Discontinued in Patients Who Fulfill Drug-Off Criteria?

Drug-free status is important for patients' quality of life if pathological CR is truly obtained. In the LAUNCH trial, the recurrence rate of patients receiving LEN+TACE followed by curative resection was not described in detail, although drug discontinuation was reported in some cases [41].

A multicenter proof-of-concept study of ABC conversion therapy [22] proposed the following criteria for drug discontinuation: (A) mRECIST CR achieved by super-selective TACE/RFA/microwave ablation, (B) sustained normalization of AFP/AFP-L3/PIVKA-II for at least 12–24 weeks, and (C) complete disappearance of arterial blood flow in the tumor determined by contrast-enhanced ultrasonography (CEUS), which has the highest sensitivity for detecting intratumoral arterial blood flow [47–60] (Table 1). Although 25 patients remained cancer-free with no recurrence of HCC after drug discontinuation, 3 of the 13 patients who did not meet the drug-off criteria and continued atezolizumab plus bevacizumab therapy had recurrence of HCC [22]. These data indicate that it is not adequate to discontinue the drug simply because the criterion for clinical CR was met. Conversely, the drug-off criterion is useful for the clinical diagnosis of pathological CR.

However, this criterion is only feasible in countries such as Japan, where tumor markers other than AFP, such as PIVKA-II and AFP-L3, can be routinely measured in clinical practice. Cases in which AFP is negative and only PIVKA-II or AFP-L3 is elevated, suggest non-pathological CR because cancer cells may be present somewhere. In such cases, it is necessary to detect intranodular arterial flow, and if it is detected, cancer-free status can be achieved by performing super-selective TACE or ablation. Although it is not necessary to perform CEUS in all cases for the management of HCC, CEUS is crucial for the decision of drug-off because CEUS is much more sensitive than CT/MRI for the detection of intranodular arterial blood flow. Thus, CEUS plays an important role in the diagnosis of pathological CR in addition to normalized AFP, AFP-L3, and PIVKA-II levels, and is thus important for determining when to discontinue the treatment drug.

There has been no proposal so far regarding the drug-off criteria for patients who have achieved CR per RECIST v1.1 (complete tumor disappearance on CT or MRI) after

receiving combination immunotherapy alone. The following criteria may be used: (A) CR by CT/MRI (RECIST v1.1), (B) persistent negative results for all three tumor markers (AFP, AFP-L3, and PIVKA-II) for at least 12–24 weeks, and (C) complete disappearance of the nodule by fusion imaging technique with CT/MRI and ultrasound [61–63]. Drug-off is considered acceptable if no Kupffer defect is found on CEUS with Sonazoid at the site of the primary tumor or if no intratumoral arterial blood flow is detected by the re-injection technique [64–67] even if a Kupffer defect is found. On the other hand, if arterial flow remains within the Kupffer defect (Defect Reperfusion) by Sonazoid CEUS, RFA under CEUS guidance [55] or fusion-image-guided ablation [61–63] can lead to true cancer-free status after drug discontinuation.

Conclusion

The combination of atezolizumab-bevacizumab and locoregional therapy has shown promising results for achieving a high rate of clinical CR in TACE-unsuitable intermediate-stage and advanced-stage HCC, in which CR is rarely achieved with locoregional therapy alone or systemic therapy alone. An increasing number of patients who achieve clinical CR with systemic therapy-based multimodal therapy are facing the choice of whether to continue or discontinue the treatment drug. The criteria for drug discontinuation remain to be sufficiently validated, and there is a lack of data on recurrence rates after drug discontinuation. Although the recently reported criteria are reliable [22], further validation study is needed.

Conflict of Interest Statement

Lecture: Eli Lilly, Bayer, Eisai, Chugai, Takeda, and AstraZeneca; grants: Taiho, Otsuka, EA Pharma, AbbVie, Eisai, Chugai, and GE Healthcare; advisory consulting: Chugai, Roche, AstraZeneca, and Eisai. Masatoshi Kudo is the Editor-in-Chief of Liver Cancer.

Funding Sources

There is no funding for this editorial.

Author Contributions

Masatoshi Kudo conceived, wrote, and approved the final manuscript.

References

- 1 Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, et al. Report of the 22nd nationwide follow-up survey of primary liver cancer in Japan (2012–2013). *Hepatol Res.* 2022;52(1):5–66.
- 2 Kudo M. Surveillance, diagnosis, and treatment outcome of hepatocellular carcinoma in Japan: 2023 update. *Liver Cancer.* 2023;12(2):95–102.
- 3 Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M. Portal vein invasion and intrahepatic micro-metastasis in small hepatocellular carcinoma by gross type. *Hepatol Res.* 2003;26(2):142–7.
- 4 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. *J Hepatol.* 2016;65(5):938–43.
- 5 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: a Japanese nationwide survey. *Hepatology.* 2017;66(2):510–7.
- 6 Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. *N Engl J Med.* 2020;382(20):1894–905.
- 7 Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. *J Hepatol.* 2022;76(4):862–73.
- 8 Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2021;22(7):991–1001.
- 9 Kudo M. Selection of systemic treatment regimen for unresectable hepatocellular carcinoma: does etiology matter? *Liver Cancer.* 2022;11:283–9.
- 10 Kudo M. The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma. *Hepatobil Surg Nutr.* 2023;12:256–60.
- 11 Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. *NEJM Evid.* 2022;1(8):EVIDo2100070.
- 12 Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. *Hepatobiliary Surg Nutr.* 2022;11(4):592–6.
- 13 Kudo M. Prioritized requirements for first-line systemic therapy for hepatocellular carcinoma: broad benefit with less toxicity. *Liver Cancer.* 2023;12:1–6.
- 14 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. *Nat Rev Clin Oncol.* 2022;19(3):151–72.
- 15 Bejjani AC, Finn RS. Hepatocellular carcinoma: pick the winner-tyrosine kinase inhibitor versus immuno-oncology agent-based combinations. *J Clin Oncol.* 2022;40(24):2763–73.
- 16 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet.* 2018;391(10126):1163–73.
- 17 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, et al. A changing paradigm for the treatment of intermediate-stage hepatocellular carcinoma: asia-pacific primary liver cancer expert consensus statements. *Liver Cancer.* 2020;9(3):245–60.
- 18 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. *Liver Cancer.* 2021;10(3):181–223.
- 19 Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. *Int J Clin Oncol.* 2022;27(7):1110–9.
- 20 Kudo M. Atezolizumab plus bevacizumab followed by curative conversion (ABC conversion) in patients with unresectable, TACE-unsuitable intermediate-stage hepatocellular carcinoma. *Liver Cancer.* 2022;11(5):399–406.
- 21 Kudo M. A novel treatment strategy for patients with intermediate-stage HCC who are not suitable for TACE: upfront systemic therapy followed by curative conversion. *Liver Cancer.* 2021;10(6):539–44.
- 22 Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H, et al. Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. *Liver Cancer.* 2023. (Epub ahead of print). <https://doi.org/10.1159/000529574>.
- 23 Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. *J Hepatol.* 2022;76(3):681–93.
- 24 European Association for the Study of the Liver Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol.* 2018;69(1):182–236.
- 25 Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. *Hepatology.* 2018;68(2):723–50.
- 26 Hasegawa K, Takemura N, Yamashita T, Watanabe T, Kaibori M, Kubo S, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of Hepatology 2021 version (5th JSH-HCC guidelines). *Hepatol Res.* 2023;53(5):383–90.
- 27 Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan society of Hepatology (JSH) 2010 updated version. *Dig Dis.* 2011;29(3):339–64.
- 28 Kudo M, Matsui O, Izumi N, Kadoya M, Okusaka T, Miyayama S, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. *Oncology.* 2014;87(Suppl 1):22–31.
- 29 Kudo M. A new treatment option for intermediate-stage hepatocellular carcinoma with high tumor burden: initial lenvatinib therapy with subsequent selective TACE. *Liver Cancer.* 2019;8(5):299–311.
- 30 Singal AG, Kudo M, Bruix J. Breakthroughs in hepatocellular carcinoma therapies. *Clin Gastroenterol Hepatol.* 2023;21(8):2135–49.
- 31 Gregory J, Dioguardi Burgio M, Corrias G, Vilgrain V, Ronot M. Evaluation of liver tumour response by imaging. *JHEP Rep.* 2020;2(3):100100.
- 32 Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, et al. Evaluation of HCC response to locoregional therapy: validation of MRI-based response criteria versus explant pathology. *J Hepatol.* 2017;67(6):1213–21.
- 33 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008;359(4):378–90.
- 34 Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol.* 2019;20(2):282–96.
- 35 Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2017;389(10064):56–66.
- 36 Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. *N Engl J Med.* 2018;379(1):54–63.
- 37 Minacapelli CD, Leuszkiewicz P, Patel A, Catalano C, Abdelsayed G, Lalos A, et al. The spontaneous regression of primary gastrointestinal malignancies: an observational review. *Cureus.* 2022;14(12):e32970.

- 38 Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. *Gut*. 2020;69(8):1492–501.
- 39 Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. *Liver Cancer*. 2022;11(4):354–67.
- 40 Kudo M, Ueshima K, Saeki I, Ishikawa T, Morimoto N, Aikata H, et al. A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial. *Liver Cancer*. 2023. (Epub ahead of print). <https://doi.org/10.1159/000531377>.
- 41 Peng Z, Fan W, Zhu B, Wang G, Sun J, Xiao C, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). *J Clin Oncol*. 2023;41(1):117–27.
- 42 Ikeda M, Yamashita T, Ogasawara S, Kudo M, Inaba Y, Morimoto M, et al. Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. *Liver Cancer*. 2023. <https://doi.org/10.1159/000531820>.
- 43 Kudo M, Guo Y, Hua Y, Zhao M, Xing W, Zhang Y, et al. TALENTACE: a phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma. *J Clin Oncol*. 2022;40(4 Suppl):TPS487.
- 44 Foerster F, Kloeckner R, Reig M, Chan SL, Chung JW, Merle P, et al. ABC-HCC: a phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. *J Clin Oncol*. 2022;40(4 Suppl):TPS498.
- 45 <https://clinicaltrials.gov/ct2/show/NCT03778957>.
- 46 El-Khoueiry AB, Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, et al. LEAP-012 trial in progress: transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC). *J Clin Oncol*. 2022;40(4 Suppl):TPS494.
- 47 Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, et al. The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid. *J Med Ultrasound*. 2020;28(2):59–82.
- 48 Dietrich CF, Nolsøe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver: update 2020–WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. *Ultraschall in der Medizin*. 2020;41:562–85.
- 49 Shiozawa K, Watanabe M, Takayama R, Takahashi M, Wakui N, Iida K, et al. Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography. *J Clin Ultrasound*. 2010;38(4):182–9.
- 50 Sugimoto K, Moriyasu F, Saito K, Rognin N, Kamiyama N, Furuichi Y, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. *Liver Int*. 2013;33(4):605–15.
- 51 Minami Y, Kudo M. Imaging modalities for assessment of treatment response to non-surgical hepatocellular carcinoma therapy: contrast-enhanced US, CT, and MRI. *Liver Cancer*. 2015;4(2):106–14.
- 52 Xia Y, Kudo M, Minami Y, Hatanaka K, Ueshima K, Chung H, et al. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: the usefulness of sonazoid-enhanced harmonic sonography. *Oncology*. 2008;75(Suppl 1):99–105.
- 53 Zhong-Zhen S, Kai L, Rong-Qin Z, Er-Jiao X, Ting Z, Ao-Hua Z, et al. A feasibility study for determining ablative margin with 3D-CEUS-CT/MR image fusion after radiofrequency ablation of hepatocellular carcinoma. *Ultraschall Med*. 2012;33(7):E250–5.
- 54 Ye J, Huang G, Zhang X, Xu M, Zhou X, Lin M, et al. Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. *Int J Hyperthermia*. 2019;36(1):55–64.
- 55 Minami Y, Kudo M, Chung H, Kawasaki T, Yagyū Y, Shimono T, et al. Contrast harmonic sonography-guided radiofrequency ablation therapy versus B-mode sonography in hepatocellular carcinoma: prospective randomized controlled trial. *AJR Am J Roentgenol*. 2007;188(2):489–94.
- 56 Choi D, Lim HK, Lee WJ, Kim SH, Kim YH, Kim SH, et al. Early assessment of the therapeutic response to radio frequency ablation for hepatocellular carcinoma: utility of gray scale harmonic ultrasonography with a microbubble contrast agent. *J Ultrasound Med*. 2003;22(11):1163–72.
- 57 Zheng SG, Xu HX, Lu MD, Xie XY, Xu ZF, Liu GJ, et al. Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma. *World J Gastroenterol*. 2013;19(6):855–65.
- 58 Kisaka Y, Hirooka M, Kumagi T, Uehara T, Hiasa Y, Kumano S, et al. Usefulness of contrast-enhanced ultrasonography with abdominal virtual ultrasonography in assessing therapeutic response in hepatocellular carcinoma treated with radiofrequency ablation. *Liver Int*. 2006;26(10):1241–7.
- 59 Qu P, Yu X, Liang P, Cheng Z, Han Z, Liu F, et al. Contrast-enhanced ultrasound in the characterization of hepatocellular carcinomas treated by ablation: comparison with contrast-enhanced magnetic resonance imaging. *Ultrasound Med Biol*. 2013;39(9):1571–9.
- 60 Frieser M, Kiesel J, Lindner A, Bernatik T, Haensler JM, Janka R, et al. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies. *Ultraschall Med*. 2011;32(2):148–53.
- 61 Minami Y, Chung H, Kudo M, Kitai S, Takahashi S, Inoue T, et al. Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation. *AJR Am J Roentgenol*. 2008;190(6):W335–341.
- 62 Song KD, Lee MW, Rhim H, Kang TW, Cha DI, Sinn DH, et al. Percutaneous US/MRI fusion-guided radiofrequency ablation for recurrent subcentimeter hepatocellular carcinoma: technical feasibility and therapeutic outcomes. *Radiology*. 2018;288(3):878–86.
- 63 Han S, Lee JM, Lee DH, Yoon JH, Chang W. Utility of real-time CT/MRI-US automatic fusion system based on vascular matching in percutaneous radiofrequency ablation for hepatocellular carcinomas: a prospective study. *Cardiovasc Intervent Radiol*. 2021;44(10):1579–96.
- 64 Kudo M. New sonographic techniques for the diagnosis and treatment of hepatocellular carcinoma. *Hepatol Res*. 2007;37(Suppl 2):S193–199.
- 65 Kudo M, Hatanaka K, Maekawa K. Defect reperfusion imaging, a newly developed novel technology using sonazoid in the treatment of hepatocellular carcinoma. *J Med Ultrasound*. 2008;16(3):169–76.
- 66 Kudo M, Hatanaka K, Maekawa K. Newly developed novel ultrasound technique, defect reperfusion ultrasound imaging, using sonazoid in the management of hepatocellular carcinoma. *Oncology*. 2010;78(Suppl 1):40–5.
- 67 Kudo M. Defect reperfusion imaging with sonazoid: a breakthrough in hepatocellular carcinoma. *Liver Cancer*. 2016;5:1–7.